91ֱ��

All publications

Journal articles

• Needham KJ, Tappenden P, Gillespie D & Whyte S (2023) . Journal of Thoracic Oncology, 18(11), S134-S134.
• Whyte S, Thomas C, Chilcott J & Kearns B (2022) . Value in Health, 25(6), 954-964.
• Thomas C, Mandrik O, Saunders CL, Thompson D, Whyte S, Griffin S & Usher-Smith JA (2021) . Cancer Prevention Research, 14(8), 811-822.
• Rubin G, Walter FM, Emery J, Hamilton W, Hoare Z, Howse J, Nixon C, Srivastava T, Thomas C, Ukoumunne OC , Usher-Smith JA et al (2021) . BMJ Open, 11(3).
• Rutter MD, Bretthauer M, Hassan C, Jover R, Adami H-O, Corley DA, Cubiella J, Cross AJ, Evelien Dekker PD, Gupta S , Kalager M et al (2020) . Gastroenterology, 158(6), 1529-1533.e4.
• Rutter MD, East J, Rees CJ, Cripps N, Docherty J, Dolwani S, Kaye PV, Monahan KJ, Novelli MR, Plumb A , Saunders BP et al (2019) . Gut, 69(2), 201-223.
• Thomas C, Whyte S, Kearns B & Chilcott JB (2019) . Value in Health, 22(10), 1154-1161.
• Kearns B, Chilcott J, Relton C, Whyte S, Woods HB, Nickerson C & Loban A (2018) . Cancer Management and Research, 10, 637-645.
• Picot J, Rose M, Cooper K, Pickett K, Lord J, Harris P, Whyte S, Böhning D & Shepherd J (2017) . Health Technology Assessment, 21(79), 1-308.
• Ren S, Minton J, Whyte S, Latimer N & Stevenson M (2017) . PharmacoEconomics.
• Uttley L, Whyte S, Gomersall T, Ren S, Wong R, Chambers D & Tappenden P (2017) . PharmacoEconomics, 35(7), 717-726.
• Faria R, Walker S, Whyte S, Dixon S, Palmer S & Sculpher M (2017) . Medical Decision Making, 37(2), 148-161.
• Kearns B, Chilcott J, Whyte S, Preston L & Sadler S (2017) . BMC Medicine, 15(1).
• Kearns B, Chilcott J, Whyte S, Preston L & Sadler S (2016) . BMC Medicine, 14(1), 200-200.
• Moore HJ, Nixon C, Tariq A, Emery J, Hamilton W, Hoare Z, Kershenbaum A, Neal RD, Ukoumunne OC, Usher-Smith J , Walter FM et al (2016) . Trials, 17(1).
• Whyte S, Dixon S, Faria R, Walker S, Palmer S, Sculpher M & Radford S (2016) . Value in Health, 19(2), 138-144.
• Kearns B, Whyte S, Seaman HE, Snowball J, Halloran SP, Butler P, Patnick J, Nickerson C & Chilcott J (2016) . British Journal of Cancer, 114(3), 327-333.
• Rowen D, Brazier J, Mukuria C, Keetharuth A, Risa Hole A, Tsuchiya A, Whyte S & Shackley P (2016) . Medical Decision Making, 36(2), 210-222.
• Hinde S, McKenna C, Whyte S, Peake MD, Callister MEJ, Rogers T & Sculpher M (2015) . British Journal of Cancer, 113(1), 135-141.
• Asaria M, Griffin S, Cookson R, Whyte S & Tappenden P (2015) . Health Economics, 24(6), 742-754.
• Kearns B, Whyte S, Chilcott J & Patnick J (2014) . British Journal of Cancer, 111(9), 1734-1741.
• Whyte S & Harnan S (2014) . Cancer Causes Control, 25(6), 647-658.
• Asaria M, Griffin S, Cookson R, Tappenden P & Whyte S (2013) . VALUE IN HEALTH, 16(7), A426-A426.
• Sharp L, Tilson L, Whyte S, Ceilleachair AO, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Barry M & Comber H (2013) . BMC Health Serv Res, 13, 105.
• Sharp L, Walsh C, Whyte S, Tilson L, O'Ceilleachair A, Usher C, Tappenden P, Chilcott J, Staines A, Barry M & Comber H (2013) . British Journal of Cancer, 108(5), 1211-1212.
• Whyte S, Pandor A & Stevenson M (2012) . Pharmacoeconomics, 30(12), 1119-1132.
• Whyte S, Chilcott J & Halloran S (2012) . Colorectal Dis, 14(9), e547-e561.
• Sharp L, Tilson L, Whyte S, O'Ceilleachair A, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Barry M & Comber H (2012) . Br J Cancer, 106(5), 805-816.
• Tilson L, Sharp L, Usher C, Walsh C, Whyte S, O'Ceilleachair A, Stuart C, Mehigan B, Kennedy MJ, Tappenden P , Chilcott J et al (2012) . European Journal of Health Economics, 13(4), 511-524.
• Madan J, Stevenson MD, Cooper KL, Ades AE, Whyte S & Akehurst R (2011) . Value Health, 14(6), 953-960.
• Whyte S, Cooper KL, Stevenson MD, Madan J & Akehurst R (2011) . Value Health, 14(4), 465-474.
• Cooper KL, Madan J, Whyte S, Stevenson MD & Akehurst RL (2011) . BMC Cancer, 11.
• Whyte S, Walsh C & Chilcott J (2011) . Medical Decision Making, 31(4), 625-641.
• Whyte S, Pandor A, Stevenson M & Rees A (2010) . Health Technol Assess, 14(Suppl. 2), 47-53.
• Whyte S, Walsh C, Sharp L, O'Ceilleachair A, Tilson L, Usher C, Chilcott J, Tappenden P, Staines A, Comber H & Barry M (2009) . Value in Health, 12(7), A395-A395.
• Sharp L, Tilson L, Whyte S, O'Ceilleachair A, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Comber H & Barry M (2009) COST-EFFECTIVENESS OF A POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAMME IN IRELAND. VALUE HEALTH, 12(7), A280-A280.
• Harnan S, Hamilton J, Simpson E, Clowes M, Navega Biz A, Whyte S, Ren S, Cooper K, Abulafi M, Ball A , Beton S et al () Faecal Immunochemical Tests For Patients With Symptoms Suggestive Of Colorectal Cancer: An Updated Systematic Review And Multiple-Threshold Meta-Analysis of Diagnostic Test Accuracy Studies. Colorectal Disease.
• Thomas C, Mandrik O & Whyte S () Modelling cost-effective strategies for minimising socioeconomic inequalities in colorectal cancer screening outcomes in England. Preventive Medicine.
• Thomas C, Mandrik O, Whyte S, Saunders CL, Griffin SJ & Usher‐Smith JA () . Cancer Reports.
• Whyte S, Pandor A, Stevenson M & Rees A () . Health Technology Assessment, 14(Suppl 2), 47-53.
• Mandrik O, Thomas C, Whyte S & Chilcott J () CALIBRATING NATURAL HISTORY OF CANCER MODELS IN THE PRESENCE OF DATA INCOMPATIBILITY; PROBLEMS AND SOLUTIONS. PharmacoEconomics.

Conference proceedings papers

• Needham KJ, Tappenden P, Gillespie D & Whyte S (2023) Model-based Evaluations of the Cost-effectiveness of Interventions for Lung Cancer: A Systematic Review. JOURNAL OF THORACIC ONCOLOGY, Vol. 18(11) (pp S134-S134)
• Kearns B, Chilcott & whyte (2016) Flexible parametric survival models and time-series analysis for extrapolating time-varying treatment effects in health technology assessment. Flexible parametric survival models and time-series analysis for extrapolating time-varying treatment effects in health technology assessment, 5 September 2016 - 8 September 2016.
• Faria R, Walker S, Whyte S, Dixon S, Sculpher M & Palmer S (2015) The value of implementation: how to invest in getting cost-effective technologies into practice. Framework and application to novel oral anticoagulants in the prevention of stroke and systemic embolism. HESG. Leeds
• Faria R, Whyte S, Palmer S & Hoomans T (2014) WORKSHOP 2999: From evaluation to implementation: how to ensure efficient investment in implementation of cost-effective technologies in clinical practice?. ISPOR. Amsterdam, 9 November 2014 - 12 November 2014.
• Rowen D, Brazier J, Mukuria C, Whyte S, Keetharuth A, Risa Hole A, Tsuchiya A & Shackley P (2014) Rowen D, Brazier J, Mukuria C, Whyte S, Keetharuth A, Risa Hole A, Tsuchiya A, Shackley P. Eliciting societal preferences for burden of illness, therapeutic improvement and end of life for value based pricing.. HESG. 91ֱ��, UK, 8 January 2014.
• Asaria M, Griffin S, Cookson R, Whyte S & Tappenden P (2013) A framework for the cost-equality analysis of health care programmes. ISPOR. Dublin
• Bessey A, Whyte S, Minton J & Chilcott J (2013) Economic evaluation of an electrical impedance spectroscopy (EIS) device used as an adjunct to colposcopy. VALUE IN HEALTH, Vol. 16(7) (pp A407-A407)
• Whyte S (2013) Cost effectiveness analysis of an early awareness campaign for colorectal cancer. Cancer Outcomes Conference. Brighton
• Whyte S (2013) Effectiveness and cost effectiveness of an awareness campaign for colorectal cancer: A mathematical modelling study. Cancer Research UK NAEDI conference. Cambridge, UK
• Whyte S (2012) The cost effectiveness of an early awareness campaign for colorectal cancer. SMDM. Oslo, Norway, 10 June 2012 - 12 June 2012.
• Whyte S, Scope A & Tappenden P (2012) The cost effectiveness of an early awareness campaign for colorectal cancer. SMDM. Oslo, Norway
• Whyte S & Chilcott J (2010) Using a natural history model in combination with screening data to estimate the test characteristics of the FOB test in the English bowel cancer screening programme. Methods for evaluating medical tests and biomarkers. Birmingham, UK
• Whyte S (2009) Bayesian calibration of a natural history model for colorectal cancer. ISPOR. Paris
• Whyte S, Dixon S, Faria R, Walker S, Sculpher M & Palmer S ()

Reports

• Srivastava T, Chambers D, Thomas C & Whyte S (2019) ECASS health economic feasibility study
• Whyte S, Thomas C, Kearns B, Webster M & Chilcott J (2017) Optimising Bowel Cancer Screening Phase 1: Optimising the cost effectiveness of repeated FIT screening and screening strategies combining bowel scope and FIT screening
• Pollard D, Cree I & Whyte S (2016) Generic Cancer Screen - Economic modelling report
• Whyte S, Chambers D & Wong R (2015) Degarelix for treating advanced hormone-dependent Prostate cancer [ID590] Spinal cord compression associated with hormonal therapy in men with hormone-dependent metastatic prostate cancer: a systematic review and economic assessment
• Faria R, Walker S, Whyte S, Dixon S, Palmer S & Sculpher M (2014) Getting cost-effective technologies into practice: the value of implementation An application to novel anticoagulants in the prevention of stroke and systemic embolism
• Whyte S, Dixon S, Faria R, Walker S, Palmer S & Sculpher M (2014) Getting cost-effective technologies into practice: the value of implementation. An application to B-type natriuretic peptide (BNP) testing in diagnosing chronic heart failure
• Walker S, Faria R, Whyte S, Dixon S, Palmer S & Sculpher M (2014) Getting cost-effective technologies into practice: the value of implementation. Report on framework for valuing implementation initiatives
• Rowen D, Brazier J, Mukuria C, Keetharuth A, Rise Hole A, Tsuchiya A, Whyte S & Shackley P (2014) Update: Eliciting societal preferences for weighting QALY's according to burden of illness, size of gain and end of life
• Whyte S, Brazier J, Rowen D, Mukuria C, Keetharuth A, RiseHole A, Tsuchiya A & Shackley P (2013) Eliciting societal preferences for burden of illness, therapeutic improvement and end of life for value based pricing: a report of the main survey
• Hinde S, McKenna C, Whyte S, Peake M, Callister M, Rogers T & Sculpher M (2012) Modelling the cost-effectiveness of early awareness interventions for the early detection of lung cancer
• Whyte S, Harnan S, Scope A, Simpson E, Tappenden P, Duffy S, Rachet B, Sculpher M, Hinde S, McKenna C & Wong R (2012) Early awareness interventions for cancer: Colorectal cancer
• Whyte S, Cooper KL, Stevenson MD, Madan J & Akehurst R (2011) Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom
• Whyte S, Cooper KL, Stevenson MD & Akehurst R (2011) Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in patients with non-Hodgkin's lymphoma in the United Kingdom (UK)
• Whyte S, Chilcott J, Essat M, Stevens J, Wong R & Kalita N (2011) Reappraisal of the options for colorectal cancer screening
• Madan J, Cooper KL, Stevenson MD, Whyte S & Akehurst R (2009) Consistency between direct trial evidence and Bayesian Mixed Treatment Comparison: Is head-to-head evidence always more reliable?
• Cooper KL, Madan J, Whyte S, Stevenson MD & Akehurst R (2009) Granulocyte colony-stimulating factors for prevention of febrile neutropenia following chemotherapy: systematic review and meta-analysis
• Sharp L, Whyte S, Ceillachair A, Comber H, Tilson L, Usher C, Walsh C, Barry M, Tappenden P, Chilcott J & Staines A (2009) Options for a population-based colorectal cancer screening programme in Ireland: a health technology assessment
• Whyte S, Chilcott J & Headley J (2008) Health economics of Colonix: A new diagnostic test in colorectal cancer

Posters

• Whyte S, Dixon S, Faria R, Walker S, Sculpher M & Palmer S The value of investing in implementation activities: A case study in natriuretic peptide testing for diagnosing suspected heart failure (SMDM 15th Biennial European Meeting 8-10 June 2015).

Preprints

• Mandrik O, Thomas C, Strong M & Whyte S (2021) Calibration and Validation of the Microsimulation Model in Cancer of the Bowel (MiMiC-Bowel), an Individual Patient Simulation Model for Investigation of the Cost-effectiveness of Personalised Screening and Surveillance Strategies..